{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:59:41Z","timestamp":1787731181340,"version":"build-2784847793"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"NIHR Academic Clinical Fellow"},{"name":"NIHR Academic Clinical Lecturer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the impact of non-medical switch from rituximab originator (RTX-O) to biosimilar (RTX-B) in patients with RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Between October 2017 and October 2019, all patients on RTX-O in our centre requiring re-treatment were switched to RTX-B unless declined by the patient or specified by the treating clinician. Switch strategy effectiveness was assessed retrospectively using DAS28-CRP(3) and RTX retention, with patients remaining on RTX-O as a comparator group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The number of patients switching to RTX-B was 255\/337 (75.7%) while 82 (24.3%) remained on RTX-O. There was no difference in DAS28-CRP(3) 4\u2009months post-RTX-B switch vs the same time point post-RTX-O previous cycle (paired data available in 60%). Eighteen-month retention estimates were 75.6% (95% CI: 69.4, 80.7%) for RTX-B group and 82.3% (95% CI: 70.4, 89.8%) for RTX-O [adjusted hazard ratio 1.52 (95% CI: 0.85, 2.73)]. The number of patients who discontinued RTX-B for loss of effectiveness (LOE) was 42\/255 (16.5%), five (2.0%) for adverse effects (AEs). Risk of RTX-B discontinuation was associated with comorbidities and \u22652 previous biologic DMARDs. Risk of adverse outcome RTX cessation was associated with comorbidities, and reduced risk with number of previous RTX-O cycles and pre-switch cycle B cell depletion. The number of patients who switched back to RTX-O was 34\/255 (13.3%) (LOE: 30, AEs: 4), while 13\/255 (5.1%) started other biologic\/targeted synthetic DMARDs. Of patients who switched back for LOE, 28\/30 remained on RTX-O at a mean 7.7\u2009months follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Non-medical switch to RTX-B was largely effective. Factors associated with RTX-B discontinuation, including comorbidities, previous biologic DMARDs, and RTX-O treatment history, may inform switch decisions. Most patients who switched back to RTX-O for LOE remained on treatment at short-term follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa834","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T22:25:13Z","timestamp":1606170313000},"page":"3679-3688","source":"Crossref","is-referenced-by-count":16,"title":["Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2604-9123","authenticated-orcid":false,"given":"Andrew R","family":"Melville","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3131-9121","authenticated-orcid":false,"given":"Md Yuzaiful","family":"Md Yusof","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fitton","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Garcia-Montoya","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Bailey","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouvik","family":"Dass","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8482","authenticated-orcid":false,"given":"Paul","family":"Emery","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya H","family":"Buch","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK"},{"name":"Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benazir","family":"Saleem","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"2021080220010295600_keaa834-B1","year":"(04  2021,   )."},{"key":"2021080220010295600_keaa834-B2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(16)00380-9","article-title":"Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial","volume":"388","author":"Porter","year":"2016","journal-title":"Lancet"},{"key":"2021080220010295600_keaa834-B3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021080220010295600_keaa834-B4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021080220010295600_keaa834-B5","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","article-title":"Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)","volume":"49","author":"Rubbert-Roth","year":"2010","journal-title":"Rheumatology"},{"key":"2021080220010295600_keaa834-B6","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","article-title":"Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological na\u00efve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab\u2019s Efficacy in MTX iNadequate rEsponders (SERENE))","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021080220010295600_keaa834-B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial","volume":"70","author":"Tak","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021080220010295600_keaa834-B8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14712598.2013.787064","article-title":"Rituximab biosimilars","volume":"13","author":"Vital","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"2021080220010295600_keaa834-B9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/19420862.2018.1433976","article-title":"Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product","volume":"10","author":"Lee","year":"2018","journal-title":"MAbs"},{"key":"2021080220010295600_keaa834-B10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2016-209540","article-title":"A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021080220010295600_keaa834-B11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40259-018-00331-4","article-title":"Long-term efficacy and safety of biosimilar ct-p10 versus innovator rituximab in rheumatoid arthritis: 48-week results from a randomized phase III trial","volume":"33","author":"Suh","year":"2019","journal-title":"BioDrugs"},{"key":"2021080220010295600_keaa834-B12","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/rheumatology\/kez152","article-title":"Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial","volume":"58","author":"Shim","year":"2019","journal-title":"Rheumatology"},{"key":"2021080220010295600_keaa834-B13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00228-018-2418-4","article-title":"The nocebo effect challenges the non-medical infliximab switch in practice","volume":"74","author":"Boone","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"2021080220010295600_keaa834-B14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/art.40324","article-title":"Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021080220010295600_keaa834-B15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jbspin.2019.01.001","article-title":"Patients\u2019 information and perspectives on biosimilars in rheumatology: a French nation-wide survey","volume":"86","author":"Frantzen","year":"2019","journal-title":"Jt Bone Spine"},{"key":"2021080220010295600_keaa834-B16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40259-019-00394-x","article-title":"Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents","volume":"34","author":"Strand","year":"2020","journal-title":"BioDrugs"},{"key":"2021080220010295600_keaa834-B17"},{"key":"2021080220010295600_keaa834-B18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2021080220010295600_keaa834-B19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/rheumatology\/key036","article-title":"Long-term persistence with rituximab in patients with rheumatoid arthritis","volume":"57","author":"Oldroyd","year":"2018","journal-title":"Rheumatology"},{"key":"2021080220010295600_keaa834-B20","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021080220010295600_keaa834-B21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3899\/jrheum.120594","article-title":"Agreement between the DAS28-CRP assessed with 3 and 4 variables in patients with rheumatoid arthritis treated with biological agents in the daily clinic","volume":"40","author":"Madsen","year":"2013","journal-title":"J Rheumatol"},{"key":"2021080220010295600_keaa834-B22","doi-asserted-by":"crossref","first-page":"h3868","DOI":"10.1136\/bmj.h3868","article-title":"How to develop a more accurate risk prediction model when there are few events","volume":"351","author":"Pavlou","year":"2015","journal-title":"BMJ"},{"key":"2021080220010295600_keaa834-B23","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3679\/39543539\/keaa834.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3679\/39543539\/keaa834.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T20:18:35Z","timestamp":1627935515000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/8\/3679\/6086019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,1,12]]},"published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa834","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,1,12]]}}}